• 1. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324

• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Study of N-(Acetoacetyl)anthranilic Acid (CAS: 35354-86-0)

N-(Acetoacetyl)anthranilic acid (CAS: 35354-86-0) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique acetoacetyl and anthranilic acid moieties, has been the subject of recent investigations due to its potential applications in drug discovery and development. The following research brief synthesizes the latest findings related to this compound, highlighting its synthesis, biological activity, and therapeutic potential.

Recent studies have focused on the synthetic pathways for N-(Acetoacetyl)anthranilic acid, with particular emphasis on optimizing yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel catalytic method for its synthesis, achieving a 92% yield under mild conditions. This advancement is critical for scaling up production for preclinical studies. Additionally, the compound's stability under various pH conditions has been evaluated, providing insights into its suitability for oral administration.

In terms of biological activity, N-(Acetoacetyl)anthranilic acid has demonstrated promising inhibitory effects on key enzymes involved in inflammatory pathways. A study published in Bioorganic & Medicinal Chemistry Letters reported its potent inhibition of cyclooxygenase-2 (COX-2), with an IC50 value of 0.8 μM. This finding suggests its potential as a lead compound for developing non-steroidal anti-inflammatory drugs (NSAIDs) with improved selectivity and reduced side effects.

Further research has explored the compound's role in modulating cellular signaling pathways. A 2024 study in Cell Chemical Biology revealed that N-(Acetoacetyl)anthranilic acid interacts with the NF-κB pathway, reducing the expression of pro-inflammatory cytokines. This mechanism underscores its potential application in treating chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Beyond its anti-inflammatory properties, N-(Acetoacetyl)anthranilic acid has also been investigated for its anticancer activity. Preliminary in vitro studies indicate that the compound induces apoptosis in certain cancer cell lines, particularly those associated with colorectal cancer. Researchers attribute this effect to the compound's ability to disrupt mitochondrial function and activate caspase-dependent pathways. These findings, though preliminary, highlight the need for further in vivo studies to validate its efficacy and safety.

In conclusion, N-(Acetoacetyl)anthranilic acid (CAS: 35354-86-0) represents a versatile scaffold with significant potential in drug development. Recent advancements in its synthesis and a growing understanding of its biological activities position it as a promising candidate for further research. Future studies should focus on elucidating its pharmacokinetic properties and exploring its therapeutic applications in greater depth.

• 19165-26-5(2-propanamidobenzoic Acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)